Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXRA | P19793 | 15/20 | 0.55 |
| ▸ | RXRB | P28702 | 4/20 | 0.53 |
| ▸ | RXRG | P48443 | 4/20 | 0.53 |
| ▸ | RARB | P10826 | 3/20 | 0.53 |
| ▸ | RARG | P13631 | 3/20 | 0.53 |
| ▸ | RARA | P10276 | 2/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.52 |
| ▸ | HNF4A | P41235 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GLA | P06280 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.50 |
| ▸ | CASP7 | P55210 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | CYP26A1 | O43174 | 2/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3982018 | 0.86 | RXRA (0.72) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6915712 | 0.85 | RXRA (0.72) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055013 | 0.82 | RXRA (0.65) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055303 | 0.82 | RXRA (0.53) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055408 | 0.81 | RXRA (0.58) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055304 | 0.81 | RXRA (0.58) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7616381 | 0.81 | RXRA (0.52) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL7422927 | 0.80 | RXRA (0.70) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL24055312 | 0.80 | RXRA (0.67) | RXRARXRBRXRGRARBRARG | |
| SCHEMBL6914131 | 0.80 | RXRA (0.76) | RXRARXRBRXRGRARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6476017-B2 | (DIBENZO(B,E)(1,4)-DIAZEPINE-11-YL)BENZOIC ACID DERIVATIVES | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2002-11-05 | — | — | US | disclosed |
| EP-0906907-B1 | COMPOUNDS POTENTIATING RETINOID | INST MED MOLECULAR DESIGN INC (JP) | 2002-03-06 | — | — | EP | disclosed |
| US-20010039272-A1 | Compounds activating pharmacological effect of retinoids | KEMPHYS LTD. (JP) | 2001-11-08 | — | — | US | disclosed |
| US-6121256-A | 4-(2,3-(2,5-DIMETHYL-2,5-HEXANO)DIBENZO(B,F)(1,4)THIAZEPINE-11 -YL)BENZOIC ACID OR SALT | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2000-09-19 | — | — | US | disclosed |
| US-5929069-A | CARBOXYPHENYL-SUBSTITUTED DIBENZO(B,F)(1,4)DIAZEPINE DERIVATIVES; TREATMENT OF VITAMIN A DEFICIENCY DISEASES, SKIN DISORDERS, LEUKEMIA | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 1999-07-27 | — | — | US | disclosed |
| EP-0906907-A1 | COMPOUNDS POTENTIATING RETINOID | Institute of Medicinal Molecular Design, Inc. (JP) | 1999-04-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010039272-A1 | Compounds activating pharmacological effect of retinoids | RXRA, RXRG, RXRB | RXRA 1/4885RXRB 3/4885RXRG 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.